HK/China Healthcare Analyst (ex-Fosun Pharma)

Xinyao (Criss) Wang

Over 15 years' experience in both finance and healthcare, covering clinic operations, investment and equity research in both China and overseas.

Pre-IPO IMPACT Therapeutics - Thoughts on the Pipeline, the Concerns and Valuation Outlook

Pre-IPO Good Doctor Cloud Healthcare & Technology Group - Pain Points of Business Models and Outlook

Pre-IPO WinHealth International Holding- A BD-Driven Model May Not Guarantee Sustainable High Growth

Equity Capital Markets

<ul>
<li>The essence of SIRIO’s business model is CDMO in the field of nutrition and health food, providing global brand owners with one-stop solutions from R&amp;D, manufacturing, packaging to marketing support.</li>
<li>The CDMO model enables SIRIO to quickly enter the global supply chain and achieve scale expansion through light-asset operations.But the stability of revenue is greatly affected by customers’ strategic adjustments.  </li>
<li>In the context of intensified homogenized competition, profit margins are easily compressed. SIRIO's equity incentive plan reflects its concerns about future growth prospects after experiencing a significant decline in 2025.</li>
</ul>


The essence of SIRIO’s business model is CDMO in the field of nutrition and health food, providing global brand owners with one-stop solutions from R&amp;D, manufacturing, packaging to marketing support.
The CDMO model enables SIRIO to quickly enter the global supply chain and achieve scale expansion through light-asset operations.But the stability of revenue is greatly affected by customers’ strategic adjustments.  
In the context of intensified homogenized competition, profit margins are easily compressed. SIRIO's equity incentive plan reflects its concerns about future growth prospects after experiencing a significant decline in 2025.


Guangdong Sirio Pharma Co Ltd (300791 CH)

Pre-IPO Sirio Pharma (A/H Listing) - About the Business Model and the Outlook